Evidence map›Paper›PMID 33222411›Full record

ArticleTransboundary and emerging diseases2021

Depletion of CD8

Michael D Baron, Sophia Hodgson, Katy Moffat, Mehnaz Qureshi, Simon P Graham, Karin E Darpel

Open access · hybridAbstract read
In one paragraph

Article in Transboundary and emerging diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Recombinant antigen P29 ofFrontiers in immunology · 2023
    Article
  3. Article
  4. Depletion of CD8Transboundary and emerging diseases · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Michael D BaronThe Pirbright Institute, Pirbright, UK.ORCID https://orcid.org/0000-0003-3395-0048
Sophia HodgsonThe Pirbright Institute, Pirbright, UK.
Katy MoffatThe Pirbright Institute, Pirbright, UK.
Mehnaz QureshiThe Pirbright Institute, Pirbright, UK.
Simon P GrahamThe Pirbright Institute, Pirbright, UK.
Karin E DarpelThe Pirbright Institute, Pirbright, UK.
The Pirbright Institute · GB

Funding

Bill and Melinda Gates Foundation OPP1098099Biotechnology and Biological Sciences Research Council BB/L014203/1Biotechnology and Biological Sciences Research Council BBS/E/I/00001728Biotechnology and Biological Sciences Research Council BBS/E/I/00001858Biotechnology and Biological Sciences Research Council BBS/E/I/00002035Biotechnology and Biological Sciences Research Council BBS/E/I/00007031Biotechnology and Biological Sciences Research Council BBS/E/I/00007037Biotechnology and Biological Sciences Research Council BBS/E/I/00007039Department for Environment, Food and Rural Affairs
6 · The paper itself

Abstract

Peste des petits ruminants (PPR) is a severe disease of goats and sheep that is widespread in Africa, the Middle East and Asia. The disease is caused by peste des petits ruminants virus (PPRV); cell culture-attenuated strains of PPRV have been shown, both experimentally and by extensive use in the field, to be effective vaccines and are widely used. We have previously demonstrated that these vaccines elicit both serological (PPRV-specific antibody) and cell-based (PPRV-specific CD4

Indexed as

Goat DiseasesPeste-des-Petits-RuminantsViral VaccinesAnimalsAntibodies, ViralCD8-Positive T-LymphocytesGoatsPeste-des-petits-ruminants virusAntibodies, ViralViral VaccinesCD8+ T cellscorrelates of protectionimmune responsePeste des petits ruminantsvaccine

Identifiers

PMID33222411
PMCPMC9291567
OpenAlexW3109725107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.